| NCT ID | NCT06805461 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenovoRx |
| Condition | Solid Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2029-09-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-08-01 with a primary completion date of 2029-09-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.
Eligibility Criteria
Eligibility Criteria: 1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure 2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06805461 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06805461 currently recruiting?
Yes, NCT06805461 is actively recruiting participants. Contact the research team at lgentry@renovorx.com for enrollment information.
Where is the NCT06805461 trial being conducted?
This trial is being conducted at Coral Gables, United States, Pittsburgh, United States, Burlington, United States.
Who is sponsoring the NCT06805461 clinical trial?
NCT06805461 is sponsored by RenovoRx. The trial plans to enroll 1,000 participants.